ANL
Adlai Nortye (ANL)
$28
About Adlai Nortye (ANL)
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
Details
Daily high
$13.54
Daily low
$12.41
Price at open
$13.54
52 Week High
$17.25
52 Week Low
$0.88
Market cap
456.0M
Dividend yield
0.00%
Volume
340
Avg. volume
616,862
P/E ratio
-13.20
Adlai Nortye News
Details
Daily high
$13.54
Daily low
$12.41
Price at open
$13.54
52 Week High
$17.25
52 Week Low
$0.88
Market cap
456.0M
Dividend yield
0.00%
Volume
340
Avg. volume
616,862
P/E ratio
-13.20